These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 31182263)

  • 1. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome.
    Deharo P; Cuisset T
    Trends Cardiovasc Med; 2020 May; 30(4):198-202. PubMed ID: 31182263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry.
    Håkansson A; Koul S; Omerovic E; Andersson J; James S; Agewall S; Mokhtari A; van Der Pals J; Wester A; Szummer K; Jernberg T; Erlinge D; Mohammad MA
    J Am Heart Assoc; 2024 Jul; 13(13):e034709. PubMed ID: 38934886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Kim W; Kim JS; Rha SW; Choi BG; Jang WY; Kang DO; Park Y; Choi JY; Roh SY; Na JO; Choi CU; Kim EJ; Park CG; Seo HS; Choi SY; Byun JK; Cha J; Oh DJ; Jeong MH;
    Heart Vessels; 2020 Sep; 35(9):1181-1192. PubMed ID: 32270356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial.
    Orban M; Trenk D; Geisler T; Rieber J; Hadamitzky M; Gross L; Orban M; Kupka D; Baylacher M; Müller S; Huber K; Koltowski L; Huczek Z; Heyn J; Jacobshagen C; Aradi D; Massberg S; Sibbing D; Hein R;
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):372-381. PubMed ID: 31855244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
    Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.
    Valgimigli M; Landi A; Angiolillo DJ; Baber U; Bhatt DL; Bonaca MP; Capodanno D; Cohen DJ; Gibson CM; James S; Kimura T; Lopes RD; Mehta SR; Montalescot G; Sibbing D; Steg PG; Stone GW; Storey RF; Vranckx P; Windecker S; Mehran R
    Circulation; 2024 Jul; 150(4):317-335. PubMed ID: 39038086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
    Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y
    Sibbing D; Aradi D; Alexopoulos D; Ten Berg J; Bhatt DL; Bonello L; Collet JP; Cuisset T; Franchi F; Gross L; Gurbel P; Jeong YH; Mehran R; Moliterno DJ; Neumann FJ; Pereira NL; Price MJ; Sabatine MS; So DYF; Stone GW; Storey RF; Tantry U; Trenk D; Valgimigli M; Waksman R; Angiolillo DJ
    JACC Cardiovasc Interv; 2019 Aug; 12(16):1521-1537. PubMed ID: 31202949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.
    Ullah W; Sandhyavenu H; Taha A; Narayana Gowda S; Mukhtar M; Reddy Polam A; Zahid S; Fischman DL; Savage MP; Rao SV; Alkhouli M
    J Am Heart Assoc; 2024 Oct; 13(20):e032490. PubMed ID: 39392170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention.
    McClure JD; Ramsay JC; Berry C
    J Am Heart Assoc; 2020 Aug; 9(16):e017109. PubMed ID: 32779497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Antiplatelet Therapy De-escalation Strategies.
    Sinnaeve PR; Adriaenssens T
    Am J Cardiol; 2021 Apr; 144 Suppl 1():S23-S31. PubMed ID: 33706987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting.
    Knijnik L; Fernandes M; Rivera M; Cardoso R; Goyal A; Liberman H; Sperling LS; McDaniel MC
    Am J Cardiol; 2021 Jul; 151():25-29. PubMed ID: 34049672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study.
    Li J; Li Y; Qiu M; Li Z; Yang J; Wang X; Bao D; Wang X; Han Y
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():579-586. PubMed ID: 31872515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.